Chemours: The Case Amidst Board Trouble (NYSE:CC)
JHVEPhoto/iStock Editorial via Getty Images Dear readers/followers, I’ve made no secret of my bullish longer-term stance on Chemours (NYSE:CC) over the past few years. The company has as of yet failed to “pop” in terms of valuation, despite what I would view as a materially attractive pricing for an attractive set of assets. However, this…